Phytopharm Plc - Product Pipeline Review - Q1 2011

Global Markets Direct, March 2011, Pages: 44

Phytopharm Plc – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Phytopharm Plc - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Phytopharm Plc - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Phytopharm Plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Phytopharm Plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Phytopharm Plc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Phytopharm Plc’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Phytopharm Plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Phytopharm Plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Phytopharm Plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Phytopharm Plc and identify potential opportunities in those areas.

List of Tables
List of Figures
Phytopharm Plc Snapshot
Phytopharm Plc Overview
Key Information
Key Facts
Phytopharm Plc – Research and Development Overview
Key Therapeutic Areas
Phytopharm Plc – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Phytopharm Plc – Pipeline Products Glance
Phytopharm Plc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Phytopharm Plc–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Phytopharm Plc – Drug Profiles
Cogane
Product Description
Mechanism of Action
R&D Progress
Cogane
Product Description
Mechanism of Action
R&D Progress
Myogane
Product Description
Mechanism of Action
R&D Progress
Cogane
Product Description
Mechanism of Action
R&D Progress
PYM60001
Product Description
Mechanism of Action
R&D Progress
PYM60086
Product Description
Mechanism of Action
R&D Progress
Phytopharm Plc – Pipeline Analysis
Phytopharm Plc – Pipeline Products by Therapeutic Class
Phytopharm Plc - Pipeline Products By Target
Phytopharm Plc – Pipeline Products by Route of Administration
Phytopharm Plc – Pipeline Products by Molecule Type
Phytopharm Plc – Recent Pipeline Updates
Phytopharm Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 17, 2010: Phytopharm Initiates Phase II Study Of Cogane In Patients With Parkinson's Disease
Jun 14, 2010: Phytopharm Receives FDA Approval To Begin Phase II Clinical Trial Of Cogane
Apr 20, 2009: Phytopharm Announces The Commencement Of Clinical Study of Cogane In Patients With Parkinson’s Disease
Dec 12, 2008: Unilever Returns Rights To Hoodia Extract
May 21, 2008: Myogane Granted European Union Orphan Medicinal Product Designation For ALS
Jan 21, 2008: Phytopharm Announces $1.16 million Funding For Cogane
Sep 24, 2007: Phytopharm Initiates Stage 3 Activities Of Joint Development Agreement For Hoodia Extract With Unilever
Jul 30, 2007: Phytopharm Completes Phase Ib Clinical Study For Myogane
Jun 05, 2007: Phytopharm plc Presents Cogane Data At ‘11th International Congress Of Parkinson’s Disease And Movement Disorders’
May 17, 2007: Phytopharm Commences Phase Ib Clinical Study For Myogane
Financial Deals Landscape
Phytopharm Plc, Deals Volume Summary, 2004 to YTD 2011
Phytopharm Plc, Deals Summary By Region, 2004 to YTD 2011
Phytopharm Plc, Deals Summary, 2004 to YTD 2011
Phytopharm Plc Detailed Deal Summary
Equity Offering
Phytopharm Completes Private Placement Of $42 Million
Phytopharm Completes Private Placement Of $17 Million
Phytopharm Completes Private Placement Of $3 Million
Phytopharm Completes Private Placement Of $12 Million
Phytopharm Enters Into Co-Development Agreement With Institute Of Radiation Medicine
Licensing Agreements
Phytopharm Enters Into Licensing Agreement With Unilever
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Phytopharm Plc – Pipeline by Therapy Area and Indication, 2011
Phytopharm Plc – Pipeline by Stage of Development, 2011
Phytopharm Plc – Monotherapy Products in Pipeline, 2011
Phytopharm Plc - Phase II, 2011
Phytopharm Plc - Phase I, 2011
Phytopharm Plc - Pipeline By Therapeutic Class, 2011
Phytopharm Plc - Pipeline By Target, 2011
Phytopharm Plc – Pipeline By Route of Administration, 2011
Phytopharm Plc – Pipeline By Molecule Type, 2011
Phytopharm Plc – Recent Pipeline Updates, 2011
Phytopharm Plc, Other Locations
Phytopharm Plc, Deals Summary, 2004 to YTD 2011
Phytopharm Plc, Deals Summary by Region, 2004 to YTD 2011
Phytopharm Plc, Deals Summary, 2004 to YTD 2011

List of Figures
Phytopharm Plc – Pipeline by Therapy Area and Indication, 2011
Phytopharm Plc – Pipeline by Stage of Development, 2011
Phytopharm Plc – Monotherapy Products in Pipeline, 2011
Phytopharm Plc – Pipeline By Therapeutic Class, 2011
Phytopharm Plc - Pipeline By Target, 2011
Phytopharm Plc – Pipeline By Molecule Type, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Ixia - Company Analysis
• SunGard - Profile - US
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Insight into Samsung Electronics' Notebook PC Business Model
• Accenture plc,(ACN) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• Advfn PLC,(AFN) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages